Why the study?
Does type-II myocardial infarction compared to type-I myocardial infarction have worse clinical outcomes in patients presenting with acute coronary syndrome?
Does type-II myocardial infarction compared to type-I myocardial infarction have worse clinical outcomes in patients presenting with acute coronary syndrome?
Patients with type-II myocardial infarction have a higher burden of comorbidities and significantly worse short- and intermediate-term mortality compared to those with type-I myocardial infarction.
Answers are grounded in this paper and cite their sources.
Type-II MI was associated with higher one-year mortality; this cohort finding leaves open optimal management strategies for this high-comorbidity population.
BACKGROUND: Type-II MI is defined as myocardial infarction (MI) secondary to ischemia due to either increased oxygen demand or decreased supply. This categorization has been used for the last five years, yet, little is known about patient characteristics and clinical outcomes. In the current work we assessed the epidemiology, causes, management and outcomes of type II MI patients. METHODS: A comparative analysis was performed between patients with type-I and type-II MI who participated in two prospective national Acute Coronary Syndrome Israeli Surveys (ACSIS) performed in 2008 and 2010. RESULTS: The surveys included 2818 patients with acute MI of whom 127 (4.5%) had type-II MI. The main causes of type-II MI were anemia (31%), sepsis (24%), and arrhythmia (17%). Patients with type-II MI tended to be older (75.6±12 vs. 63.8±13, p<0.0001), female majority (43.3% vs. 22.3%, p<0.0001), had more frequently impaired functional level (45.7% vs. 17%, p<0.0001) and a higher GRACE risk score (150±32 vs. 110±35, p<0.0001). Patients with type-II MI were significantly less often referred for coronary interventions (36% vs. 89%, p<0.0001) and less frequently prescribed guideline-directed medical therapy. Mortality rates were substantially higher among patients with type-II MI both at thirty-day (13.6% vs. 4.9%, p<0.0001) and at one-year (23.9% vs. 8.6%, p<0.0001) follow-ups. CONCLUSIONS: Patients with type-II compared to type-I MI have distinct demographics, increased prevalence of multiple comorbidities, a high-risk cardiovascular profile and an overall worse outcome. The complex medical condition of this cohort imposes a great therapeutic challenge and specific guidelines with recommended medical treatment and invasive strategies are warranted.
No takes yet. Share an insight, caveat, or question.
Stein et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: